(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
The Nasdaq Capital Market |
Exhibit No. | Description | |||||||
99.1 |
Bellicum Pharmaceuticals, Inc. | ||||||||||||||||||||
Dated: March 24, 2022 | By: | /s/ Richard A. Fair | ||||||||||||||||||
Richard A. Fair | ||||||||||||||||||||
President and Chief Executive Officer | ||||||||||||||||||||
BELLICUM PHARMACEUTICALS, INC. | |||||||||||||||||||||||
Consolidated Balance Sheets | |||||||||||||||||||||||
(unaudited; in thousands) | |||||||||||||||||||||||
December 31 | December 31, | ||||||||||||||||||||||
2021 | 2020 | ||||||||||||||||||||||
Current Assets: | |||||||||||||||||||||||
Cash and cash equivalents | $ | 46,156 | $ | 35,495 | |||||||||||||||||||
Restricted cash | 1,501 | 1,501 | |||||||||||||||||||||
Accounts receivable, interest and other receivables | 205 | 2 | |||||||||||||||||||||
Prepaid expenses and other current assets | 1,269 | 802 | |||||||||||||||||||||
Assets held for sale | — | 1,643 | |||||||||||||||||||||
Non-Current Assets: | |||||||||||||||||||||||
Operating lease right-of-use assets | — | 645 | |||||||||||||||||||||
Property and equipment, net | 12 | 189 | |||||||||||||||||||||
Other assets | — | 307 | |||||||||||||||||||||
Total assets | $ | 49,143 | $ | 40,584 | |||||||||||||||||||
Current Liabilities: | |||||||||||||||||||||||
Accounts payable | $ | 90 | $ | 891 | |||||||||||||||||||
Accrued expenses and other current liabilities | 3,849 | 4,165 | |||||||||||||||||||||
Warrant derivative liability | 2,773 | 10,345 | |||||||||||||||||||||
Private placement option liability | — | 7,803 | |||||||||||||||||||||
Current portion of lease liabilities | — | 825 | |||||||||||||||||||||
Liabilities held for sale | — | 672 | |||||||||||||||||||||
Long-Term Liabilities: | |||||||||||||||||||||||
Long-term lease liabilities | — | 344 | |||||||||||||||||||||
Preferred stock | 18,036 | 18,036 | |||||||||||||||||||||
Total stockholders' equity (deficit) | 24,395 | (2,497) | |||||||||||||||||||||
Total liabilities, preferred stock and stockholders' equity (deficit) | $ | 49,143 | $ | 40,584 |
BELLICUM PHARMACEUTICALS, INC. | ||||||||||||||||||||||||||
Consolidated Statements of Operations | ||||||||||||||||||||||||||
(unaudited; in thousands, except share and per share amounts) | ||||||||||||||||||||||||||
Three Months Ended | Year Ended | |||||||||||||||||||||||||
December 31, | December 31, | |||||||||||||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||||||||||||
Revenues | ||||||||||||||||||||||||||
Supply agreement | $ | — | $ | — | $ | 700 | $ | — | ||||||||||||||||||
License revenue | 500 | 500 | 5,500 | 500 | ||||||||||||||||||||||
Total revenues | 500 | 500 | 6,200 | 500 | ||||||||||||||||||||||
Operating Expenses: | ||||||||||||||||||||||||||
Research and development | 4,047 | 8,706 | 23,578 | 39,052 | ||||||||||||||||||||||
General and administrative | 1,551 | 3,436 | 7,010 | 15,531 | ||||||||||||||||||||||
Total operating expenses | 5,598 | 12,142 | 30,588 | 54,583 | ||||||||||||||||||||||
Impairment of property and equipment | — | (1,265) | — | (1,265) | ||||||||||||||||||||||
Gain (loss) on dispositions, net | — | (105) | (478) | 3,656 | ||||||||||||||||||||||
Loss from operations | (5,098) | (13,012) | (24,866) | (51,692) | ||||||||||||||||||||||
Interest income | — | — | 32 | 387 | ||||||||||||||||||||||
Interest expense | — | (191) | (4) | (2,659) | ||||||||||||||||||||||
Change in fair value of warrant and private placement option liabilities | 7,619 | 31,874 | 15,126 | 46,130 | ||||||||||||||||||||||
Gain on extinguishment of debt | — | 112 | — | 112 | ||||||||||||||||||||||
Other income (expense) | 10 | — | 7 | — | ||||||||||||||||||||||
Net income (loss) | $ | 2,531 | $ | 18,783 | $ | (9,705) | $ | (7,722) | ||||||||||||||||||
Less: undistributed earnings to participating securities | (716) | (10,984) | — | — | ||||||||||||||||||||||
Net income (loss) attributable to common shareholders | $ | 1,815 | $ | 7,799 | $ | (9,705) | $ | (7,722) | ||||||||||||||||||
Net income (loss) per share attributable to common shareholders, basic | $ | 0.12 | $ | 0.99 | $ | (0.84) | $ | (1.34) | ||||||||||||||||||
Net income (loss) per share attributable to common shareholders, diluted | $ | 0.11 | $ | 0.98 | $ | (0.84) | $ | (1.34) | ||||||||||||||||||
Weighted-average shares outstanding, basic | 15,712,196 | 7,873,402 | 11,504,294 | 5,760,159 | ||||||||||||||||||||||
Weighted-average shares outstanding, diluted | 15,817,832 | 7,935,532 | 11,504,294 | 5,760,159 |
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
Cover |
Mar. 24, 2022 |
---|---|
Entity Addresses [Line Items] | |
Document Type | 8-K |
Document Period End Date | Mar. 24, 2022 |
Entity Registrant Name | Bellicum Pharmaceuticals, Inc. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-36783 |
Entity Tax Identification Number | 20-1450200 |
Entity Address, Address Line One | 3730 Kirby Drive |
Entity Address, Address Line Two | Ste. 1200 |
Entity Address, City or Town | Houston |
Entity Address, State or Province | TX |
Entity Address, Postal Zip Code | 77098 |
City Area Code | 281 |
Local Phone Number | 454-3424 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.01 per share |
Trading Symbol | BLCM |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0001358403 |
Amendment Flag | false |
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end
?0X
M'Z_C9 \6][3$>?UZ<63FP_Z0_^[PQ=/_@=02P,$% @ X(IX5!$D&%#.
M'P :Z,! !\ !E>&@Y.3$R,#(Q<31E87)N:6YG +7HHPW60G423+&L1A.>)P"I!]EPA301 /S])$EE,XK] U2%MPLUPLBX6TQ&W.= CDNO3[S98F/+>V)A 5CPU52JG.@\:
M*X"AV'4"\_5E:1H\5XV&I/@3F?+*QP#KA)FKBIL+.\-;6$_0#Y&L+MAC[<,D
M&!'*$:%N>FUFE">2^'6C7)G1IDLJ$@0^L,5+88CHLT0=E&XA\J$T4V(*L;A(7<8*Q65LN(
MT>A\?$7GXW>2C]^E6$YD# S;'Q6PA:YIJB^5*G2DVA*F@#V@?E^8J!A-GA:T
MCV@88@VLPT3D'JURE],N^H!HJJ%\-O-FN57_8<_:R@^_L,KRZX!B4O)S$F.Q
M,$K>QO7(FA5IEV(YU+XZ2<9*)CZ)N=>64:]7C(K9))$<-KR0S7:*9:G!(S#
MS"/#D/58B.@LGPJFDRV3*XS2BF<7/